Ampio puts $7M into Denver facility; Cambrex API plant gets FDA OK; Hanford scores low-cost volts;

> Ampio Pharmaceuticals will spend $7 million to equip a site in the Denver Tech Center of Colorado, so that it can manufacture commercial-scale versions of its investigational product. Report

> L.B. Bohle, which manufactures pharmaceutical processing and handling equipment, has spent about $6.8 million to build a new manufacturing facility in Ennigerloh, Germany. Release

> Cambrex says its active pharmaceutical ingredient plant in Charles City, IA, has passed an FDA inspection with no Form 483 observations. Report

> The FDA has posted a job listing to hire a new director for its office of compliance. Listing

> Novartis' ($NVS) generic unit Sandoz says that it had started a late-stage clinical trial with its biosimilar version of AbbVie's ($ABV) best-selling drug Humira, the sixth biosimilar to go into Phase III trials. Story

> The FDA says that compounder Abrams Royal Pharmacy is voluntarily recalling all unexpired lots of sterile products dispensed nationwide due to concerns of lack of sterility assurance. http://www.fda.gov/Safety/Recalls/ucm379313.htm

And Finally... Hanford Pharmaceuticals in Syracuse, NY, will get low-cost electricity through a state program in exchange for adding 54 jobs as part of a manufacturing plant expansion. Story